IDAP: ANTIBODY TECHNOLOGY PLATFORM

Viventia’s proprietary discovery and development engine addresses the fundamental considerations in the advancement of antibody-based therapeutics:

• Accessibility to novel targets
• Efficacious drug design
• Potent mechanism of action
• Cost-effective production

By employing its innovative IDAP (Immune Driven Antibody Platform) technology, the Company delivers both: a portfolio of novel cancer-associated targets and, human antibodies validated for tumor reactivity that can be reengineered according to Viventia’s unique immunotoxin format.

The key benefit of Viventia’s discovery process is the simultaneous validation of druggable oncology targets with the identification of fully-human antibodies for clinical development.

The IDAP advantage includes, but not limited to:
 

• Selection of novel human, tumor-specific antibodies with no to minimal normal tissue reactivity using functional assays
• Antibody selection on live cells does not limit screening to known targets
• Development of potent oncology products against solid tumors using a targeted payload strategy
• Identification of novel cell surface tumor targets at the level of the protein (proteome)  

Armed with this powerful technology platform, Viventia has demonstrated that within a period of one year, ten preclinical candidates were identified from the screening of 200,000 clones from an immune library.  Fully realized, IDAP has the capability to effectively mine the human immune response to disease not only within the cancer field, but across the entire therapeutic spectrum.  The IDAP technology therefore represents a novel, complementary adjunct to other antibody technologies, as well as an integrated, standalone, ‘target-to-clinic’ engine as a feeder to the Company’s product development.   

Immune Driven Antibody Platform (IDAP) Components

Fusogenics™
Captures the patient’s immune response to tumor associated antigens in a library format. Antibodies are screened in a functional assay using a semi-automated HTP process.

UnLock™
Isolation and identification of membrane-associated tumor markers. Serves as engine for identification of known and novel cell-surface targets. Has identified 14 new potential cancer drug targets and continues to discover new targets at a rate of one to two per quarter at the current scale.